Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Mar 14, 2023
How to Start Trading Penny Stocks

How to Start Trading Penny Stocks

Penny stocks have been unfairly dismissed by the investment community as being overly risky, often due to negative stereotypes perpetuated by media portrayals like Leonardo DiCaprio's character in The Wolf of Wall Street. However, it's important to recognize that not all penny stocks are created equal and that many of them have the potential to generate substantial returns at a low cost. To trade penny stocks successfully, one must conduct thorough research, possess shrewd trading abilities, and gain experience through practice. With this in mind, here are four compelling reasons to consider trading penny stocks.

Reason #1: Penny Stocks are Affordable

It's no secret that high-profile stocks like Apple, Google, and Tesla can cost hundreds or even thousands of dollars per share. This means that traders would need a considerable amount of money to see significant returns. In contrast, penny stocks are a more affordable option, although they come with higher risks and potential for greater returns.

Consider this: with $1,000, you could purchase a single share of Tesla. To make a 50% profit of $500, Tesla would need to rise to $1,500, which could take a while. Alternatively, with that same $1,000, you could purchase over 600 shares of a penny stock trading at $1.50 per share. If that penny stock jumped to $2 per share, you would make the same $500 profit. A 50 cent increase could even happen in a single day.

Reason #2: Researching Penny Stocks is Possible

It's true that penny stocks are often associated with small-cap companies with limited financial information and management history. This can make it difficult for traders to conduct thorough due diligence. However, there are tools available to help evaluate penny stock companies.

Tickeron, for example, has developed a range of fundamental analysis metrics for assessing different types of stocks, including penny stocks. The best part is that artificial intelligence (AI) is used to conduct this analysis automatically.

To access Tickeron's tools, simply go to the Screener Home page on their website, select Penny Stocks, and review the range of fundamental analysis metrics powered by AI.

Tickeron's fundamental analysis goes beyond the simplistic use of P/E ratios or price-to-sales ratios. Using algorithms, Tickeron conducts more insightful analysis.

The Outlook Rating is generated by analyzing the ratio of advancing to declining daily volume from the past month.

The Valuation Rating is based on a proprietary formula that takes into account a set of traditional fundamentals and generates an AI-estimated price per share for the company. This estimate is then compared to the current stock price, determining whether the stock is overvalued or undervalued. A rating of 1 indicates that the stock is significantly undervalued according to Tickeron's AI.

The Profit vs Risk Rating evaluates a company's performance by considering the balance between profit, volatility, and drawdown.

The SMR (Sales, Margin, Return on Equity) Rating is based on a comparative analysis of weighted sales, income margin, and return on equity values in comparison to S&P 500 index constituents. The proprietary weighted SMR value helps identify companies with strong and profitable business models.

The Price Growth Strength Rating is based on a comparative analysis of stock price increases or decreases over the last twelve months in comparison to S&P 500 index constituents. Short-term positions are determined by ranking price changes over a period of 1 or 3 months, while long-term positions track price changes over 6 or 12 months. A rating of 1 points to the highest price growth, while a rating of 100 indicates the lowest price growth.

Finally, the P/E Growth Rating is based on a comparative analysis of a stock's P/E ratio increase over the last twelve months in comparison to S&P 500 index constituents. A rating of 1 indicates the highest P/E growth, while a rating of 100 indicates the lowest P/E growth.

Tickeron's AI runs an entire range of technical analysis indicators, including patterns and common indicators such as Bollinger Bands, Moving Averages, and Stochastics. Traders can utilize all of these tools on Tickeron's Screener to evaluate stocks and/or sort them by their preferred fundamental or technical analysis indicators.

Researching penny stocks is no longer a challenging task with Tickeron's innovative approach.

Reason #3: Embrace Volatility as Your Ally

While it's true that penny stocks can be highly volatile, this volatility can often work in a trader's favor. In fact, volatility is frequently seen as a trader's closest ally.

To illustrate this point, we used Screener Home to select Penny Stocks and sorted them by daily volume, seeking penny stocks with significant volume over the past month. The following snapshot shows what Tickeron's A.I. generated:

Over the past month, several penny stocks have experienced significant price fluctuations, with some ranging from -90.9% to +135.45%. Because penny stocks have low prices, small changes can result in significant gains or losses for traders, whether they are buying or selling. As a result, traders must scrutinize numerous data points and cross-reference them with various indicators (both fundamental and technical), as well as leverage volatility to their advantage. Tickeron offers the necessary tools to achieve this goal. 

Reason #4: Practice Trading Penny Stocks Risk-Free

At Tickeron, both novice and seasoned traders can practice trading penny stocks without the risk of real money through our "Paper Trading" feature. This tool enables traders to experiment with our proprietary indicators and artificial intelligence and formulate a trading strategy that suits their personal style. You can easily access this feature by visiting the Tickeron Home Page and clicking on "My Paper Trades" to create a portfolio consisting of stocks, ETFs, or mutual funds and monitor your progress over time.

If you're new to Tickeron, they have an introductory 2-minute video tutorial on how to create and manage a 'virtual portfolio' in just a few simple steps. Additionally, while using Tickeron's Screener to explore trading opportunities and assess various penny stocks, you'll notice a "Paper Trades" icon next to each ticker name, enabling you to effortlessly add the selected stock to your online portfolio.

Penny Stocks: A Risky Investment, But with Trading Tools You Can Minimize the Risk

Investing in penny stocks can be riskier than investing in major stocks traded on big exchanges like the Nasdaq and NYSE. However, with proper research, due diligence, and trading tools, you can navigate the penny stock market and potentially reap substantial profits.

Before jumping into the penny stock market, it's wise to develop a sound trading strategy and gain experience through practice. Tickeron's Paper Trading feature enables investors and traders to build hypothetical portfolios and make trades using the platform's fundamental and technical analysis indicators. With time, you can refine your strategy, determine which indicators work best for you, and even identify specific penny stocks to target for trading.

It's important to note that trading penny stocks isn't suitable for everyone, and as previously mentioned, it's a high-risk investment with the potential for significant gains or losses. However, if you're prepared to take on the risks, it's crucial to use as many tools as possible to inform your trades. Tickeron provides a range of tools to help you make informed decisions and minimize your risk in the penny stock market.

Tickeron's Products

The main idea behind technical analysis is the ability to find recurring price patterns and trends and use them to predict the direction of future market trends. We started with the creation of AI-based Engines (Pattern Search Engine, Real-Time Patterns, Trend Prediction Engine) that allow us to effectively analyze market trends.  We then have explored almost all existing methods (price patterns, trend indicators, oscillators, and many others) using neural networks and deep historical backtests. As a result, it was possible to form a pool of trading algorithms that together allow our AI Robots to effectively determine the key points of change in market trends.


Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
How to Start Trading Penny Stocks